Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human Prolactin for Lactation Induction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women, aged 18-45 years~* Prolactin deficiency due to congenital deficiency, surgery or radiation, or Sheehan's syndrome during the current or previous pregnancies, for women who desire to breastfeed their infants.~* Postpartum at the time of study participation~* Milk must fail to come in by 2-4 days after delivery.~* Prolactin levels will be less than the lower limit of normal for the assay performed. If a subject is postpartum, prolactin levels will be less than the normal range for postpartum women (\<= 138.0 ± 11.9 ng/mL).~* Free T4 index must be normal either on or off thyroid hormone replacement.~* Fasting am cortisol or 1 hour Cortrosyn 0.25 mg stimulated cortisol must be normal (\>18 mg/dL). If it is not normal, subjects must be on glucocorticoid replacement and have no symptoms of adrenal insufficiency.~* History of normal spontaneous puberty or Tanner stage V breast development after previous estrogen replacement therapy.~Exclusion Criteria:~* Current use of medications known to increase or decrease prolactin~* Anatomical breast abnormalities~* Previous mammoplasty~* Breast augmentation~* Current use of hormonal contraception~* Allergies to mannitol~* Medications contraindicated for breastfeeding mothers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- recombinant human prolactin treatment (Type: EXPERIMENTAL): Open label twice daily recombinant human prolactin

Based on this trial design, predict the completion outcome and termination type (if applicable).